Rubius Therapeutics, Inc. Secures $75 Million Loan Facility
21 déc. 2018 12h15 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, today...
Rubius Therapeutics Added to Nasdaq Biotechnology Index
17 déc. 2018 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, today...
Rubius Therapeutics to Present at Evercore ISI HealthCONx Conference
19 nov. 2018 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, announced...
Rubius Therapeutics Reports Third Quarter 2018 Financial Results and Operational Progress
13 nov. 2018 08h00 HE
|
Rubius Therapeutics
On Track to Submit First IND for RTX-134 in Q1 2019 CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new...
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
06 nov. 2018 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, announced...
Rubius Therapeutics to Announce Third Quarter 2018 Financial Results
05 nov. 2018 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, plans to...
Rubius Therapeutics to Participate in the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
20 sept. 2018 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...
Rubius Therapeutics Added to Russell 2000 and 3000 Indexes
14 sept. 2018 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...
Rubius Therapeutics to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference
04 sept. 2018 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...
Rubius Therapeutics Reports Second Quarter 2018 Financial Results
31 août 2018 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...